Celsion Corporation (CLSN)

[Biobonic]

The second interim is based on the 158th death in the trial group.

From today's PR

LAWRENCEVILLE, N.J., April 15, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug-development
company, announces that the prescribed minimum number of events of 158 patient deaths has been reached for the second pre-specified interim
analysis of the OPTIMA Phase III Study with ThermoDox® plus RFA (radiofrequency ablation) in patients with hepatocellular carcinoma (HCC), or primary liver cancer. Following preparation of the data, the Independent Data Monitoring Committee (iDMC) is expected to meet in July to conduct the
second interim analysis. Celsion expects to announce iDMC recommendations as soon as possible after the meeting.